ENSC heads into its May 20 earnings event carrying the most aggressive short-side lending profile it has seen all year — a violent, week-long repricing that leaves the stock at $0.28 and the borrow market in a state of near-crisis.
The positioning story for Ensysce Biosciences is almost entirely about what happened in the lending market this week. Short interest was running below 0.5% of the free float as recently as May 8. By May 12 it had jumped to 7.4% — a more than 15-fold increase in three sessions. The estimated short position on May 14 is 5.5% of the free float, still more than ten times where it was the previous Friday. Cost to borrow has followed in lockstep: it ran near 76–80% APR through late April and early May, then accelerated sharply — hitting 130% on May 11, 158% on May 12, 206% on May 13, and reaching 235% by May 14. That is a three-fold increase in a single week. At 235%, the cost to carry a short position is extreme even by small-cap biotech standards.
The ORTEX short score captures the shift cleanly. It held in the 41–42 range for the entire first week of May, consistent with low short interest and loose borrow. From May 11 it jumped to 63, then 72 on May 12 and 13, before easing back to 69 on May 14 — still the highest range the score has occupied since data collection. The days-to-cover rank sits at the 99th percentile, meaning almost no stock in the universe carries a higher DTC relative to its normal trading volume.
Availability has tightened in step with the borrow cost surge, though it has not gone fully dark. The lending pool was near-empty earlier in the week — availability ran below 5% on May 11 and May 12. By May 14 it had loosened slightly to levels consistent with roughly two-thirds of available shares being on loan, still well inside the range that would normally be described as comfortable. The 52-week peak availability was near 96%, so the current tightening represents a structural change in the lending market, not a brief blip.
What triggered the sudden demand for borrows is not explicit in the data, but the timing maps directly onto the upcoming May 20 event. Recent earnings history for ENSC offers some context on reaction patterns. The March 24 print produced a 1-day move of -4.7% and a 5-day drift of -8.0%. A January 7 event generated an initial pop of +5.0% that then reversed to -7.9% over the following week. The March 30 announcement was a mild exception — up 2.1% on the day, up 6.0% over five sessions. The pattern across these events is asymmetric drift: initial day moves are modest in both directions, but the 5-day tape tends to follow the bears. Short sellers building positions at 235% borrow cost ahead of the print are making an expensive bet.
Options data from this ticker is stale by several years and has not been incorporated here. Institutional ownership is thin — Anson Group holds 4.4% and Adage Capital Management 1.6%, with the remainder fragmented across small quant and index positions. There is no material recent insider activity. Valuation data is stale and has been omitted. What matters next is simple: whether May 20 delivers a catalyst that justifies the highest borrow costs ENSC has seen all year — or forces a rapid unwind of a position that is already expensive to hold.
See the live data behind this article on ORTEX.
Open ENSC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
